We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+59.91%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$255M
AUM Growth
-$103M
Cap. Flow
-$140M
Cap. Flow %
-54.73%
Top 10 Hldgs %
45.35%
Holding
89
New
26
Increased
17
Reduced
12
Closed
26

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$7.51M
2
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$6.07M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$3.74M
4
MORF
Morphic Holding, Inc. Common Stock
MORF
+$3.67M
5
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$3.24M

Top Sells

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$12.9M
2
SNY icon
Sanofi
SNY
+$11.4M
3
ESTA icon
Establishment Labs
ESTA
+$8.21M
4
KURA icon
Kura Oncology
KURA
+$5.92M
5
AZN icon
AstraZeneca
AZN
+$5.64M

Sector Composition

Rank Sector Weight
1 Healthcare 81.4%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KDNY
1
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$21.4M 8.41%
818,035
+4,037
+0.5% +$89.4K
MDGL icon
2
Madrigal Pharmaceuticals
MDGL
$12.8B
$20.3M 7.97%
70,000
-30,000
-30% -$2.93M
BMY icon
3
PUT
Bristol-Myers Squibb
BMY
$124B
$12.6M 4.94%
+175,000
New +$13.2M
ESTA icon
4
Establishment Labs
ESTA
$2.72B
$12.5M 4.91%
190,767
-135,901
-42% -$8.21M
ASND icon
5
Ascendis Pharma A/S
ASND
$17.1B
$8.67M 3.4%
70,997
-29,003
-29% -$3.37M
BMRN icon
6
BioMarin Pharmaceuticals
BMRN
$11.5B
$8.28M 3.25%
+80,000
New +$7.51M
RXDX
7
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$8.25M 3.24%
75,000
+50,000
+200% +$3.24M
VRNA
8
DELISTED
Verona Pharma
VRNA
$8.17M 3.2%
312,498
-37,502
-11% -$499K
VTYX
9
DELISTED
Ventyx Biosciences
VTYX
$7.89M 3.09%
240,623
+70,623
+42% +$2.09M
MORF
10
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$7.51M 2.95%
280,921
+134,430
+92% +$3.67M
ACLX
11
DELISTED
Arcellx
ACLX
$7.44M 2.92%
240,143
+30,005
+14% +$688K
CBAY
12
DELISTED
Cymabay Therapeutics
CBAY
$7.17M 2.81%
1,143,531
-146,980
-11% -$559K
ATXS
13
DELISTED
Astria Therapeutics
ATXS
$7.04M 2.76%
472,482
+72,439
+18% +$747K
CERE
14
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$6.78M 2.66%
+215,000
New +$6.07M
NARI
15
DELISTED
Inari Medical, Inc. Common Stock
NARI
$5.72M 2.24%
90,000
-30,000
-25% -$2.18M
MRNA icon
16
PUT
Moderna
MRNA
$24.5B
$5.39M 2.11%
+30,000
New +$4.91M
AMGN icon
17
PUT
Amgen
AMGN
$198B
$5.25M 2.06%
+20,000
New +$5.36M
HZNP
18
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$5.12M 2.01%
+45,000
New +$3.74M
RCKT icon
19
Rocket Pharmaceuticals
RCKT
$376M
$5.05M 1.98%
258,115
-9,679
-4% -$178K
CLDX icon
20
Celldex Therapeutics
CLDX
$2.77B
$4.9M 1.92%
110,000
+30,000
+38% +$1.07M
BLU
21
DELISTED
BELLUS Health Inc.
BLU
$4.72M 1.85%
573,678
+100,081
+21% +$933K
AZN icon
22
AstraZeneca
AZN
$262B
$4.07M 1.6%
30,000
-45,000
-60% -$5.64M
CYTK icon
23
Cytokinetics
CYTK
$10.9B
$4.01M 1.57%
87,601
+22,601
+35% +$972K
KURA icon
24
Kura Oncology
KURA
$964M
$3.34M 1.31%
268,747
-407,006
-60% -$5.92M
VKTX icon
25
Viking Therapeutics
VKTX
$4.31B
$3.29M 1.29%
350,000
+100,000
+40% +$446K
1
2 3 4

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q4 2022 Portfolio in Review

As of Q4 2022, Affinity Asset Advisors held 89 positions worth $255M, down 29% from $358M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Affinity Asset Advisors withdrew a net $140M in Q4 2022, closing 26 positions and reducing 12 holdings. Its most notable exit was Global Blood Therapeutics, Inc., an estimated $12.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, up from 51% a quarter earlier, followed by Financials.

Against the trend, Affinity Asset Advisors opened a new position in BioMarin Pharmaceuticals worth $8.28M.

  • Affinity Asset Advisors's largest Q4 2022 buy was BioMarin Pharmaceuticals: 80,000 shares worth $8.28M.
  • Affinity Asset Advisors added most to Morphic Holding, Inc. Common Stock in Q4 2022, an estimated $3.67M increase.
  • Affinity Asset Advisors's biggest Q4 2022 reduction was Establishment Labs, cutting an estimated $8.21M.
  • Affinity Asset Advisors fully exited Global Blood Therapeutics, Inc. in Q4 2022, selling an estimated $12.9M.
  • Affinity Asset Advisors's ten largest holdings make up 45% of its $255M portfolio in Q4 2022.
  • Affinity Asset Advisors opened 26 new positions and closed 26 in Q4 2022.
  • Affinity Asset Advisors's portfolio value fell 29% quarter-over-quarter to $255M.

Based on Affinity Asset Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.